In The News
The Change Maker Series – Vicki Vakiener
Meet Vicki Vakiener - Commercial Business Consultant, Chimerix - Member Board of Directors, and serious bargain hunter. Vicki Vakiener, a leader in marketing and commercial operations speaks to us about her career journey, her optimism about healthcare, and the one piece of advice she would share on navigating your career. [...]
The Change Maker Series – Deanna Darlington
Meet Deanna Darlington - Principal at Innopiphany, avid traveler, and foodie. Deanna Darlington, a leader in patient engagement and health equity speaks to us about her career journey, her passion for change, and what makes her tick. https://innopiphany.com/the-change-maker-series-deanna-darlington/five-questions/
Digital DNA Enables the Real-World Evidence Ecosystem to Improve Patient Outcomes
Cultivating Digital DNA (Data, Networks, and Applications) Enables a Thriving Real-World Evidence Ecosystem to Improve Patient Outcomes An evolution of medical diagnostics, treatments, and services relies upon a multitude of trusted vendors collectively developing “Digital DNA” — scaled medical datasets, diverse provider networks, and cutting-edge software applications. by Allison Robbins, [...]
Radar On – December 2018: HHS Proposal Could Reduce Costs but May Harm Patient Care
Radar On – December 2018: HHS Proposal Could Reduce Costs but May Harm Patient Care "If the proposed changes to the protected classes are implemented, “the effect on patients and prescribers will be greater delay, less choice or options and more administrative/time costs to secure the treatments that are best [...]
Radar On – October 2018: HHS Wants to See WACs in TV Ads
Radar On – October 2018: HHS Wants to See WACs in TV Ads “Transparency in the prices of health care services is always a good thing — but finding the prices of drugs is generally easier for patients to find than other health care services that they get. More importantly, [...]
Radar On – September 2018: CVS Will Exclude Certain Drugs Based on ICER Analyses of QALY
Radar On – September 2018: CVS Will Exclude Certain Drugs Based on ICER Analyses of QALY “The question is how this will affect innovative drugs where there are fewer alternatives for patients. Any decision to use this approach needs to also be carefully evaluated in the context of how it [...]